Santiago González-Santiago

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer

Nicoletta Colombo, Gloria S. Huang, Giovanni Scambia et al. · Journal of Clinical Oncology · 2018 · 97 citations · Full text

Medicine, Genetics, Oncology +13

SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)

Santiago González-Santiago, Teresa Ramón y Cajal, Elena Aguirre et al. · Clinical & Translational Oncology · 2019 · 72 citations · Full text

Life Sciences, Genetics, Oncology +17

SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

Antonio Llombart‐Cussac, Begoña Bermejo, Cristian Villanueva et al. · Breast Cancer Research and Treatment · 2015 · 41 citations · Full text

Medicine, Oncology, Pharmacology +15

Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain

I. Esteban, Marta Vilaró, Encarna Adrover et al. · Psycho-Oncology · 2018 · 38 citations

Life Sciences, Genetics, Psychology +15